BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-134@catalystbrief.girapphe.com
DTSTAMP:20261117T181602Z
LAST-MODIFIED:20261117T181602Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Celltrion — CT-P44(Daratumumab) [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Compare Pharmacokinetics
 \, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combi
 nation With Lenalidomide and Dexamethasone in Patients With Refractory or 
 Relapsed Multiple Myeloma.\nSource: https://clinicaltrials.gov/study/NCT06
 952478\nhttps://catalystbrief.girapphe.com/e/134?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/134?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
